2-methoxy-5-methylnaphthoquinone | 174769-24-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 2-methoxy-5-methylnaphthoquinone
• 英文别名: 2-Methoxy-5-methylnaphthalene-1,4-dione
• CAS: 174769-24-5
• 化学式: C₁₂H₁₀O₃
• 分子量: 202.21
• InChiKey: GGNYOQIPPACJQD-UHFFFAOYSA-N

物化性质

• 沸点：
  378.6±42.0 °C(Predicted)
• 密度：
  1.24±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-methoxy-5-methylnaphthoquinone 在 sodium azide 、 硫酸 作用下， 反应 20.0h， 生成 3-methoxy-6-methyl-1H-1-benzazepine-2,5-dione
  参考文献：
  名称：

  3-羟基-1H-1-苯并ze庚因-2,5-二酮的类似物：N-甲基-D-天冬氨酸受体甘氨酸位点的结构-活性关系。

  摘要：

  合成了一系列3-羟基-1H-1-苯并enza庚因-2,5-二酮（HBAD）的芳香族和氮杂环戊烷环修饰的类似物，并在NMDA受体甘氨酸位点对其进行了评估。芳香环修饰的HBAD通常是通过与取代的2-甲氧基萘-1,4-二酮进行Schmidt反应，然后进行去甲基化来制备的。苯并ze庚因3-甲基醚的亲电芳族取代得到7-取代的类似物。多取代的2-甲氧基萘-1，4-二酮的制备通过Diels-Alder方法进行，利用取代的丁二烯与2-甲氧基苯醌进行随后的芳构化。还研究了结构修饰，例如消除芳环，除去3-羟基和羟基从C-3到C-4的转移。使用[3H] MK801结合试验对NMDA拮抗作用进行了初步评估。通过[3H] -5,7-二氯尿嘧啶酸（DCKA）甘氨酸位点结合测定法进一步评估了表现出通过抑制[3H] MK801结合而显示出NMDA拮抗剂活性的HBAD。使用非洲爪蟾卵母细胞和培养的大鼠皮质神经元的电生理测定

  DOI：

  10.1021/jm960479z
• 作为产物：
  描述：

  2-甲氧基对苯二酚 在 manganese(IV) oxide 、 sodium periodate 、 溴 、 溶剂黄146 作用下， 以 氯仿 、 甲苯 为溶剂， 反应 97.25h， 生成 2-methoxy-5-methylnaphthoquinone
  参考文献：
  名称：

  3-羟基-1H-1-苯并ze庚因-2,5-二酮的类似物：N-甲基-D-天冬氨酸受体甘氨酸位点的结构-活性关系。

  摘要：

  合成了一系列3-羟基-1H-1-苯并enza庚因-2,5-二酮（HBAD）的芳香族和氮杂环戊烷环修饰的类似物，并在NMDA受体甘氨酸位点对其进行了评估。芳香环修饰的HBAD通常是通过与取代的2-甲氧基萘-1,4-二酮进行Schmidt反应，然后进行去甲基化来制备的。苯并ze庚因3-甲基醚的亲电芳族取代得到7-取代的类似物。多取代的2-甲氧基萘-1，4-二酮的制备通过Diels-Alder方法进行，利用取代的丁二烯与2-甲氧基苯醌进行随后的芳构化。还研究了结构修饰，例如消除芳环，除去3-羟基和羟基从C-3到C-4的转移。使用[3H] MK801结合试验对NMDA拮抗作用进行了初步评估。通过[3H] -5,7-二氯尿嘧啶酸（DCKA）甘氨酸位点结合测定法进一步评估了表现出通过抑制[3H] MK801结合而显示出NMDA拮抗剂活性的HBAD。使用非洲爪蟾卵母细胞和培养的大鼠皮质神经元的电生理测定

  DOI：

  10.1021/jm960479z

文献信息

• Azepine synthesis via a diels-alder reaction
  申请人：State of Oregon, acting by and through The Oregon State Board of Higher

  公开号：US05476933A1

  公开（公告）日：1995-12-19

  Disclosed are methods of preparing azepines by a multistep synthesis including a Diels-Alder reaction. Also disclosed are methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating or preventing opiate tolerance are disclosed by administering to an animal in need of such treatment an azepine which has high binding to the NMDA glycine site.

  揭示了通过多步合成包括 Diels-Alder 反应制备环庚烯的方法。还揭示了治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术相关的神经元丢失的方法，以及治疗包括阿尔茨海默病、肌萎缩侧索硬化症、亨廷顿病和唐氏综合征在内的神经退行性疾病，治疗或预防兴奋性氨基酸过度活跃的不良后果，以及治疗焦虑、慢性疼痛、抽搐、诱导麻醉和治疗或预防阿片耐受性的方法，通过向需要此类治疗的动物施用对 NMDA 甘氨酸位点具有高结合能力的环庚烯来实现。
• Azepine compounds
  申请人：State of Oregon, Acting by and through The Oregon State Board of Higher

  公开号：US05708168A1

  公开（公告）日：1998-01-13

  Disclosed are methods of preparing azepines by a multistep synthesis including a Diels-Alder reaction. Also disclosed are methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, inducing anesthesia and treating or preventing opiate tolerance are disclosed by administering to an animal in need of such treatment an azepine which has high binding to the NMDA glycine site.

  本发明涉及一种通过多步合成包括Diels-Alder反应制备氮杂环庚烯的方法。同时，本发明还涉及一种通过给予具有高结合NMDA甘氨酸位点的氮杂环庚烯来治疗或预防与中风、缺血、中枢神经系统创伤、低血糖和手术有关的神经元丢失，以及治疗阿尔茨海默病、肌萎缩性侧索硬化、亨廷顿病和唐氏综合征等神经退行性疾病，治疗兴奋性氨基酸过度活跃的不良后果，以及治疗焦虑、慢性疼痛、惊厥、诱导麻醉和治疗或预防鸦片类药物耐受性的方法。
• RADICAL POLYMERIZATION CONTROL AGENT AND RADICAL POLYMERIZATION CONTROL METHOD
  申请人：Kawasaki Kasei Chemicals Ltd.

  公开号：US20210122692A1

  公开（公告）日：2021-04-29

  A conventional polymerization inhibitor is for example an agent to scavenge radicals generated during storage of a radical polymerizable compound and used to stably handle the radical polymerizable compound, but is unnecessary when the radical polymerizable compound is to be subjected to radical polymerization reaction, and is preferably removed at the time of the radical polymerization reaction. The object of the present invention is to obviate inconvenience of removing the polymerization inhibitor at the time of radical polymerization. The radical polymerization control agent contained in a radical polymerizable composition of the present invention functions as a radical polymerization inhibitor for example stored in a dark place, but loses its radical polymerization inhibiting effect when polymerization is initiated while being irradiated with light at a certain specific wavelength at the time of polymerization. Thus, radical polymerization of the radical polymerizable compound is easily initiated without increasing the amount of a radical polymerization initiator. That is, the radical polymerization control agent of the present invention is a radical polymerization control agent which is a corn pound having an effect to inhibit radical polymerization of a radical polymerizable compound and which loses the radical polymerization inhibiting effect under irradiation with light rays containing light within a wavelength range of from 300 nm to 500 nm.
• US5476933A
  申请人：——

  公开号：US5476933A

  公开（公告）日：1995-12-19
• US5708168A
  申请人：——

  公开号：US5708168A

  公开（公告）日：1998-01-13